Working... Menu

Rapamycin In Angiomyolipomas In Patients With Tuberous Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01217125
Recruitment Status : Completed
First Posted : October 8, 2010
Last Update Posted : March 8, 2012
Ministry of Health, Spain
Information provided by (Responsible Party):
Roser Torra, Fundacio Puigvert

Brief Summary:
The purpose of this study is to determine whether rapamycin is safe and effective in the treatment of renal angiomyolipomas in patients with tuberousclerosis.

Condition or disease Intervention/treatment Phase
Angiomyolipoma Drug: Sirolimus Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : October 2008
Actual Primary Completion Date : May 2011
Actual Study Completion Date : May 2011

Intervention Details:
  • Drug: Sirolimus
    plasma levels between 4 and 8
    Other Name: Rapamune

Primary Outcome Measures :
  1. Angiomyolipoma volume [ Time Frame: 2 years ]
    Measured by MRI

Secondary Outcome Measures :
  1. skin lesions, AML complications, [ Time Frame: 2 years ]
    Evaluate skin lesions Collect event realted to AML

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   10 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Diagnosis of tuberousclerosis Angiomyolipoma >2cm age>10 years

Exclusion Criteria:

Creatinine >4 No recent AML bleeding No hepatic abnormalities (liver tests 2fold) Hematocrit<27% Thrombocytopenia (<100.000/mm3) Leukopenia (<3000/mm3) Ischemic cardiopathy Recent surgery (2 months prior to enrollment) Pregnancy Serum cholesterol over 7.8 mmol/l or hypertriglyceridemia fasten(>4.6 mmol/l) non controlled with drugs malignancy in the previous 2 years allergy to macrolides

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01217125

Sponsors and Collaborators
Fundacio Puigvert
Ministry of Health, Spain
Layout table for investigator information
Principal Investigator: Roser Torra, MD,PhD Fundacio Puigvert, Barcelona

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Roser Torra, MD, PhD, Fundacio Puigvert Identifier: NCT01217125     History of Changes
Other Study ID Numbers: EudraCT 2007-005978-30
First Posted: October 8, 2010    Key Record Dates
Last Update Posted: March 8, 2012
Last Verified: March 2012

Keywords provided by Roser Torra, Fundacio Puigvert:
tuberousclerosis, angiomyolipoma, rapamycin

Additional relevant MeSH terms:
Layout table for MeSH terms
Tuberous Sclerosis
Neoplasms, Multiple Primary
Neoplastic Syndromes, Hereditary
Malformations of Cortical Development, Group I
Malformations of Cortical Development
Nervous System Malformations
Nervous System Diseases
Neurocutaneous Syndromes
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Congenital Abnormalities
Genetic Diseases, Inborn
Neoplasms, Adipose Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Perivascular Epithelioid Cell Neoplasms
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Antifungal Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs